Phase Ib/II Results for TP53-Mutant MDS and AML

Video

David Sallman, MD, assistant member, Department of Malignant Hematology, Moffitt Cancer Center, explains the significance of the initial results from a recent phase 1B/2 trial combining APR-246 and azacitidine (Vidaza) in patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia.

David Sallman, MD, assistant member, Department of Malignant Hematology, Moffitt Cancer Center, explains the significance of the initial results from a recent phase Ib/II trial combining APR-246 and azacitidine (Vidaza) in patients with TP53-mutant myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).

Out of 12 patients enrolled in the trial, 9 patients were found evaluable. Eight of these patients had achieved complete remission, Sallman said.

Related Videos
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Jamie Koprivnikar, MD, and Hana Safah, MD, experts on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Related Content